貝萊德世界健康科學基金 Hedged A2 港幣
以盡量提高總回報為目標。基金將不少於70%的資產投資於全球各地主要從事保健、製藥、醫學科技 及生物科技供應及開發業務的公司之股票。 本基金亦可投資於其他新興市場（例如巴西、南非及南韓）。
Director of BlackRock since 2016. Prior to joining BlackRock in 2008, Mr. Liu was a Partner and Biotech Analyst at Mehta Partners. Mr. Liu began his investment career in 2000 and has a BS from the University of Science & Technology (China), an MBA from the University of Chicago and a PhD degree in Chemistry from Yale University.
Director of BlackRock since 2011. Mr. Lee began his investment career in 2006 and has a BA from Princeton University
Ms. Xie is the managing director and Portfolio Manager of BlackRock Advisor since 2006. Before becoming part of BlackRock Advisors in 2005, she was with State Street Research & Management since 2001. Ms. Xie began her investment career as a pharmaceutical analyst for Sanford Bernstein in 1999.